Kura Oncology Inc (NASDAQ:KURA) – Wedbush reduced their Q1 2018 earnings estimates for Kura Oncology in a research note issued on Wednesday. Wedbush analyst R. Driscoll now expects that the company will earn ($0.36) per share for the quarter, down from their previous forecast of ($0.31). Wedbush has a “Buy” rating and a $19.00 price target on the stock. Wedbush also issued estimates for Kura Oncology’s Q2 2018 earnings at ($0.36) EPS, Q3 2018 earnings at ($0.38) EPS, Q4 2018 earnings at ($0.40) EPS, FY2018 earnings at ($1.50) EPS, FY2019 earnings at ($1.63) EPS, FY2020 earnings at ($1.64) EPS and FY2021 earnings at $0.09 EPS.
KURA has been the topic of a number of other reports. Citigroup set a $28.00 price target on Kura Oncology and gave the company a “buy” rating in a report on Friday, February 16th. BidaskClub upgraded Kura Oncology from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 22nd. Zacks Investment Research upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Thursday, February 8th. Cann reiterated a “buy” rating and issued a $30.00 price target on shares of Kura Oncology in a report on Friday, February 16th. Finally, ValuEngine downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $21.67.
Kura Oncology stock opened at $19.80 on Monday. Kura Oncology has a fifty-two week low of $5.90 and a fifty-two week high of $24.02. The stock has a market capitalization of $660.41, a price-to-earnings ratio of -12.86 and a beta of 4.10. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.44 and a quick ratio of 13.48.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01).
Hedge funds have recently made changes to their positions in the stock. MetLife Investment Advisors LLC purchased a new position in Kura Oncology during the 4th quarter worth $155,000. American International Group Inc. grew its stake in Kura Oncology by 42.0% during the 4th quarter. American International Group Inc. now owns 13,574 shares of the company’s stock worth $208,000 after buying an additional 4,012 shares during the last quarter. New York State Common Retirement Fund purchased a new position in Kura Oncology during the 2nd quarter worth $142,000. California State Teachers Retirement System purchased a new position in Kura Oncology during the 2nd quarter worth $235,000. Finally, Virtus Fund Advisers LLC purchased a new position in Kura Oncology during the 4th quarter worth $392,000. Hedge funds and other institutional investors own 64.65% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/19/q1-2018-eps-estimates-for-kura-oncology-inc-cut-by-wedbush-kura.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.